BUZZ-Seelos Therapeutics surges on deal with U.S. Army to develop PTSD drug

Reuters09-24

** Shares of Seelos Therapeutics jumps ~89% to 35 cents premarket

** Co says it has signed agreement with a U.S. Army unit to supply its drug candidate, which is being developed for treatment of post-traumatic stress disorder

** Ketamine-based drug, SLS-002, will be tested in active-duty service members and veterans with PTSD in mid-stage study

** Trial, funded by the U.S. Department of Defense's health agency, is expected to start dosing before the end of 2024 - SEEL

** PTSD, a disorder caused by very stressful events, affects 13 million Americans and is commonly associated with war veterans

** As of last close, stock down ~98% YTD

(Reporting by Mariam Sunny in Bengaluru)

((Mariam.ESunny@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment